How to use Atara Biotherapeutics Inc. ATRA as a Forecasting Tool ...

The 36-month beta value for ATRA is at 0.45. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.” The public float ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago. These ...

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago. These ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There was no apparent catalyst for the increase. The stock has been highly volatile since it went public in March: It quadrupled in value over a five-week span before plunging by 41% over the past ...

US stocks traded lower on Monday as investors turned their attention to the presidential election on Tuesday. More than 76 million Americans have voted via mail-in ballots or early in person ...

While a stock dropping after beating expectations is never good, there's another warning sign Microsoft is exhibiting, and it could spell further trouble ahead. In the first quarter, Microsoft ...